Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | MC5R | P33032 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | CHKA | P35790 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6306233 | 0.98 | ACHE (0.70) | ACHEKMT2APKMMC4RMC5R | |
| SCHEMBL4841995 | 0.91 | ACHE (0.64) | ACHEKMT2APKMMC4RMC5R | |
| SCHEMBL2637536 | 0.91 | ACHE (0.64) | ACHEKMT2APKMMC4RMC5R | |
| SCHEMBL4842070 | 0.91 | ACHE (0.64) | ACHEKMT2APKMMC4RMC5R | |
| Trifluoroacetic Acid SCHEMBL1921350 | 0.87 | MCHR1 (0.58) | ACHEKMT2AMCHR1SIGMAR1 | |
| SCHEMBL31307777 | 0.86 | NPC1 (0.57) | ACHEKMT2AMEN1MCHR1SIGMAR1 | |
| SCHEMBL9593130 | 0.84 | CCR3 (0.61) | ACHEMCHR1 | |
| SCHEMBL6186952 | 0.84 | HRH3 (0.69) | ACHEKMT2APKMSIGMAR1 | |
| SCHEMBL27999347 | 0.84 | KMT2A (0.89) | ACHEKMT2APKMMC4RMC5R | |
| SCHEMBL13499607 | 0.84 | ACHE (1.00) | ACHEKMT2APKMMC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023014611-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | YEH, TENG-KUANG (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-113166078-A | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | 伊迪亚生物科学有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-1622914-B1 | NEW PIPERIDINYLAMINO-THIENO[2,3-D] PYRIMIDINE COMPOUNDS | TROVIS PHARMACEUTICALS LLC (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-1966191-B1 | SUBSTITUTED PYRAZINONE DERIVATIVES AS ALPHA2C-ADRENORECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-17 | — | — | EP | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ANDRE-GIL JOSE IGNACIO | 2008-10-30 | — | — | US | disclosed |
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| EP-1737840-B1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2007-09-12 | — | — | EP | disclosed |
| EP-0234098-B1 | N-[piperidylaminocarbonyl]quinolinecarboxamide derivatives having psychotropic activity | JOHN WYETH & BROTHER LIMITED (GB) | 1992-02-26 | — | — | EP | disclosed |
| US-4985438-A | PSYCHOTROPIC ACTIVITY, ANTIDEPRESSANTS | JOHN WYETH & BROTHER, LIMITED (GB) | 1991-01-15 | — | — | US | disclosed |
| US-4806552-A | ANTIDEPRESSANTS | JOHN WYETH & BROTHER, LIMITED (GB) | 1989-02-21 | — | — | US | disclosed |
| US-4778802-A | PSYCHOTROPIC ACTIVITY; ANTIDEPRESSANTS | JOHN WYETH & BROTHER, LTD. (GB) | 1988-10-18 | — | — | US | disclosed |
| US-4722930-A | ANTIDEPRESSANTS | JOHN WYETH AND BROTHER LIMITED (GB) | 1988-02-02 | — | — | US | disclosed |
| EP-0234098-A1 | N-[piperidylaminocarbonyl]quinolinecarboxamide derivatives having psychotropic activity | JOHN WYETH & BROTHER LIMITED (GB) | 1987-09-02 | — | — | EP | disclosed |
| US-4563466-A | ANTISEROTONINE | JOHN WYETH & BROTHER LIMITED (GB) | 1986-01-07 | — | — | US | disclosed |
| EP-0035374-B1 | PIPERIDYL - UREA, - THIOUREA AND - GUANIDINE DERIVATIVES, AND INTERMEDIATES THEREFOR, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-01-30 | — | — | EP | disclosed |
| US-4426387-A | Piperid-4-yl ureas and thio ureas used as anti-depressant agents | JOHN WYETH & BROTHER LTD. (GB) | 1984-01-17 | — | — | US | disclosed |
| EP-0035374-A2 | Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1981-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269251-A1 | Substituted Pyrazinone Derivatives as Alpha2C-Adrenoreceptor Antagonists | ADRA2C, ADRB2, ADRA2A | ACHE 174/4885KMT2A 1686/4885PKM 1765/4885 |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | ACHE 4091/4885KMT2A 1007/4885PKM 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.